Skip to content

MDMA and psilocybin regulate oligodendrocyte-lineage cell numbers and anxiety-like behaviors in a rat model of fear.

Mehmet Bostancıklıoğlu, Davut Sinan Kaplan, Ramazan Bal, Elif Yiğit, Hasan Ulusal, Ebru Temiz

Biological Psychiatry February 3, 2026 DOI: 10.1016/j.biopsych.2026.01.016 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Experimental study in an animal model Peer reviewed
Sample size 210
Population Adult male Wistar rats
Interventions Psilocybin MDMA
Dose 0.5 mg/kg psilocybin or 0.1 mg/kg/day MDMA for four days
Duration Four-day intervention
Topics MDMA Psilocybin Anxiety
Keywords Fear-related behaviors Myelination Oligodendrocyte plasticity Oligodendrogenesis
Key findings Psilocybin and MDMA promote adult oligodendrocyte and myelin plasticity, and this myelin remodeling is necessary for their anxiolytic effects in a rat model of contextual fear conditioning.

Abstract

Psilocybin and 3,4-methylenedioxymethamphetamine (MDMA) produce rapid, enduring therapeutic effects in post-traumatic stress disorder (PTSD); however, the underlying cellular mechanisms remain incompletely understood. This study investigated whether adult myelin plasticity contributes to the therapeutic actions of psilocybin and MDMA in a rat model of contextual fear conditioning. Adult male Wistar rats (n = 210) received repeated low doses of psilocybin (0.5 mg/kg, i.p., for four days) or MDMA (0.1 mg/kg/day, i.p., for four days). Behavioral tests assessed anxiety-like behaviors and spatial memory. Following local and global manipulations of myelin integrity, we assessed the drugs' effects on myelination by quantifying myelin sheath thickness, oligodendrocyte-lineage cell densities, and transcriptomic, proteomic, and metabolomic profiles in the dentate gyrus. Both compounds reduced anxiety-like behaviors. These improvements coincided with oligodendroglial changes and multi-omic signatures of myelin-related remodeling; mean g-ratio measures of myelin thickness, however, did not differ significantly between intact fear-conditioned animals with or without psychedelic treatment. Myelin disruption abolished these anxiolytic effects, and integrative multi-omics revealed convergent upregulation of myelin-related proteins following administration of psilocybin or MDMA. Psilocybin preferentially induced early oligodendroglial gene programs, while MDMA enhanced markers of mature myelin. Notably, 5-HT2A receptor blockade completely abolished the myelin and behavioral enhancements induced by both psilocybin and MDMA. Psilocybin and MDMA promote adult oligodendrocyte and myelin plasticity. Enhancing myelination might be a viable strategy to augment or sustain the therapeutic effects of psychedelic-assisted treatments for PTSD and related disorders.

In the evidence

This study is part of the evidence base for a synthesis in the library. Here is how each one recorded it.

  • Psilocybin and MDMA reduced anxiety-like behaviors in a rat model of contextual fear conditioning, and myelin disruption abolished these anxiolytic effects.

    Synthesized

Comparable studies

Other preclinical and animal studies on MDMA for anxiety, most cited first.

Study Year Design Participants
3,4-Methylenedioxymethamphetamine facilitates fear extinction learning Mice 2015 Preclinical experimental study
Effects of acute social stress on the conditioned place preference induced by MDMA in adolescent and adult mice Adolescent (postnatal day 29-40) and adult (postnatal day 50-61) male mice 2014 Experimental study
MDMA in Adolescent Male Rats Adolescent male rats (postnatal day 45) 2006 Controlled experiment n = 12
Psychedelics: A review of their effects on recalled aversive memories and fear/anxiety expression in rodents Rodents 2024 Review
Differential behavioral outcomes of 3,4-methylenedioxymethamphetamine (MDMA-ecstasy) in anxiety-like responses in mice 2-month-old Balb/c male mice (25-35 g) 2013 Observational study n = 70

Explore topics

By condition and practice